The Agency for Medicines and Medical Devices of BiH allowed the placement of Cuban medicine CimaVax EGF on the market of BiH. It is used in the treatment of lung cancer.
From the Agency was said that the approval license was issued on the basis of positive ratings regarding the quality, efficiency and safety, and the relation benefit-risk that was procured in the procedure of issuing the permit of putting a medicine on the market of BiH, was satisfying.
In the statement was noted that the experience and results obtained in the current application of medicine indicate satisfactory safety profile.
CimaVax prevents spreading of metastases and turns lung cancer into a chronic disease, as explained by Cuban immunologist from the Centar for molecular immunology in Havana, Camilo Rodriguez.
He added that the best results are achieved in patients with microcellular type of lung cancer, where it is expected for the patient to live for up to five years.
Around 3,000 patients in Cuba received this vaccine in the first four years of application.